Cisplatin-vinorelbine chemotherapy in non-small cell lung cancer is safe and well tolerated: results of a retrospective Hungarian clinical data analysis.

Objective: The efficacy of cisplatin–vinorelbine chemotherapy (CT) in NSCLC is well established. In this retrospective data analysis, haematological safety and tolerability, furthermore the effects of cisplatin–vinorelbine combination on patients' quality of life (QoL) are examined by reviewing the clinical data of NSCLC patients in a retrospective manner. Research design/methods: All patients (n = 25) received the following regimen: cisplatin (80 mg/m2 on day 1 by i.v. infusion) and vinorelbine (30 mg/m2 on days 1 and 8 by i.v. infusion; 21-day cycles; patients received four cycles of CT). Haematological laboratory and QoL data on day 1 of all cycles were collected. Quality of life was assessed by reviewing the data of patients' charts considering physical limitation, fatigue, nausea, vomiting, diarrhoea, constipation, social activities, fever, appetite and weight loss. The absence of problems was scored as 0, moderate complaints as 1 and serious deterioration as 2. Results: The QoL data showed no signif...